Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer

被引:21
|
作者
Zhang, Yingsheng [1 ,2 ]
Wu, Meng-Ju [3 ,4 ]
Lu, Wan-Chi [5 ]
Li, Yi-Chuan [6 ,7 ]
Jang, Chun Ju [5 ,6 ]
Yang, Jer-Yen [6 ,7 ,8 ]
机构
[1] Cedars Sinai Med Ctr, Dept Med & Biol Sci, Los Angeles, CA 90048 USA
[2] Cedars Sinai Samuel Oschin Comprehens Canc Inst, Dept Surg, Los Angeles, CA 90048 USA
[3] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA
[4] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
[5] China Med Univ, Inst Biochem & Mol Biol, Taichung 406040, Taiwan
[6] China Med Univ, Canc Biol & Precis Therapeut Ctr, Taichung 406040, Taiwan
[7] China Med Univ, Dept Biol Sci & Technol, Taichung 406040, Taiwan
[8] China Med Univ, Grad Inst Biomed Sci, Taichung 406040, Taiwan
关键词
PYRUVATE-KINASE M2; CLINICAL-FEATURES; PROTEIN-PROTEIN; STEM-CELLS; ISOFORM; INHIBITION; ENHANCERS; PATTERNS; REVEALS; TARGETS;
D O I
10.1016/j.cmet.2023.12.003
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic reprogramming is key for cancer development, yet the mechanism that sustains triple -negative breast cancer (TNBC) cell growth despite deficient pyruvate kinase M2 (PKM2) and tumor glycolysis remains to be determined. Here, we find that deficiency in tumor glycolysis activates a metabolic switch from glycolysis to fatty acid b -oxidation (FAO) to fuel TNBC growth. We show that, in TNBC cells, PKM2 directly interacts with histone methyltransferase EZH2 to coordinately mediate epigenetic silencing of a carnitine transporter, SLC16A9. Inhibition of PKM2 leads to impaired EZH2 recruitment to SLC16A9, and in turn de -represses SLC16A9 expression to increase intracellular carnitine influx, programming TNBC cells to an FAO -dependent and luminal-like cell state. Together, these findings reveal a new metabolic switch that drives TNBC from a metabolically heterogeneous -lineage plastic cell state to an FAO -dependent -lineage committed cell state, where dual targeting of EZH2 and FAO induces potent synthetic lethality in TNBC.
引用
收藏
页码:193 / 208.e8
页数:25
相关论文
共 50 条
  • [41] Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
    Munkacsy, Gyongyi
    Santarpia, Libero
    Gyorffy, Balazs
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [42] The role of metabolic reprogramming in immune escape of triple-negative breast cancer
    Bao, Ruochen
    Qu, Hongtao
    Li, Baifeng
    Cheng, Kai
    Miao, Yandong
    Wang, Jiangtao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [43] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [44] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [45] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [46] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [47] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [48] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [49] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [50] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600